All In Biotech

NDA 207981 · Taiho Oncology

Lonsurf

Tipiracil Hydrochloride, Trifluridine · Oral · Nucleoside Analog Antiviral; Nucleoside Metabolic Inhibitor

NovelOrphan

Last checked: Nov 20, 2026Latest source record: Aug 2, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2015

Sep 22, 2015

Approved uses

3

Original approval plus efficacy supplements

Registered trials

185

32 Phase 3, 43 recruiting

FAERS reports

10,823

8,549 serious, 4,240 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Nov 5, 2025.

LONSURF is a combination of trifluridine, a nucleoside metabolic inhibitor, and tipiracil, a thymidine phosphorylase inhibitor, indicated for the treatment of adult patients with: metastatic colorectal cancer as a single agent or in combination with bevacizumab who have been previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-VEGF biological therapy, and if RAS wild-type, an anti-EGFR therapy. ( 1.1 ) metastatic gastric or gastroesophageal junction adenocarcinoma previously treated with at least two prior lines of chemotherapy that included a fluoropyrimidine, a platinum, either a taxane or irinotecan, and if appropriate, HER2/neu-targeted therapy. ( 1.2 ) 1.1 Metastatic Colorectal Cancer LONSURF, as a single agent or in combination with bevacizumab, is indicated for the treatment of adult patients with metastatic colorectal cancer previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-VEGF biological therapy, and if RAS wild-type, an anti-EGFR therapy. 1.2 Metastatic Gastric Cancer LONSURF is indicated for the treatment of adult patients with metastatic gastric or gastroesophageal junction adenocarcinoma previously treated with at least two prior lines of chemotherapy that included a fluoropyrimidine, a platinum, either a taxane or irinotecan, and if appropriate, HER2/neu-targeted therapy.

Mechanism: LONSURF consists of a thymidine-based nucleoside analog, trifluridine, and the thymidine phosphorylase inhibitor, tipiracil, at a molar ratio 1:0.5 (weight ratio, 1:0.471). Inclusion of tipiracil increases trifluridine exposure by inhibiting its metabolism by thymidine phosphorylase. Following uptake into cancer cells, trifluridine is incorporated into DNA, interferes with DNA synthesis and inhibits cell proliferation. Trifluridine/tipiracil demonstrated anti-tumor activity against KRAS wild-type and mutant human colorectal cancer xenografts in mice.

Therapeutic areas: Infectious disease and vaccines

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Aug 2, 2023 Supplement 12 · Efficacy · priority review OrphanLabelLetterReview
  • Feb 22, 2019 Supplement 8 · Efficacy · priority review OrphanLabelLetter
  • Sep 22, 2015 Original approval · Type 1 - New Molecular Entity and Type 4 - New Combination NovelOrphanLabelReviewSummary Review
2 products under this application
  • LONSURF · TIPIRACIL HYDROCHLORIDE EQ 6.14MG BASE; TRIFLURIDINE 15MG · TABLET, ORAL · Prescription · TE AB
  • LONSURF · TIPIRACIL HYDROCHLORIDE EQ 8.19MG BASE; TRIFLURIDINE 20MG · TABLET, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Tipiracil" as an intervention, any sponsor and status, largest first.

All 185 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • death3,101
  • disease progression1,795
  • fatigue1,435
  • nausea1,202
  • diarrhoea1,040
  • decreased appetite695
  • vomiting649
  • asthenia510
  • white blood cell count decreased500
  • anaemia375
  • drug ineffective370
  • neutropenia362

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
201557
20161,355
20171,424
20181,345
2019944
2020964
2021971
2022870
20231,042
2024752
2025639
2026460

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Lonsurf (Trifluridine/Tipiracil HCl)

2024 spending

$226M

Beneficiaries

3,946

18,692 claims

Per beneficiary

$57,252

$245.25 per unit

View as table
YearSpending
2020$107,441,017
2021$117,240,905
2022$142,418,647
2023$176,155,837
2024$225,915,435

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 130 on PubMed

Sponsor: Taiho Oncology

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.